LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) is a translational medicine service provider with 10 years of delivering innovations in oncology translational research and immuno oncology. Founded in 2011 by overseas returnees Drs. Danyi Wen, Yizhun Zhu, et al, LIDE brings together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. We operate at the forefront of new technologies and adopt the highest international accreditation standards.



LIDE offers traditional CRO services like NGS, CR (conditionally reprogrammed) cell lines and has a collection of more than 1500 patient derived xenograft (PDX) models covering 40+ cancer types, of which 200+ are special drug resistant and/or genetically altered. More importantly, LIDE specializes in using its proprietary MiniPDX and Kcell Assay Kit to offer Functional Diagnosis - an evolved approach to drug r&d that maximizes budget efficiency and minimizes time to validation.



LIDE differentiates itself from other CROs by continually conducting self-funded internal research of its immense tumor bio bank, and working with KOLs in the academic space to vigorously promote the development and application of translational medical research in China. We also adopt the highest international operational standards. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.

Biotechnology

Life Sciences

Research

Therapeutics

LIDE Biotech

LIDE Biotech's headquarters in Shanghai, China

Description

People

Jobs